SCHEMBL6353535

SCHEMBL6353535

Cc1cccc(S(=O)(=O)Nc2ccc3ccc4c(C(N)=O)nn(-c5ccc(S(N)(=O)=O)cc5)c4c3c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.44
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
PTGS2 P35354 3/20 0.42
CA1 P00915 6/20 0.41
CA2 P00918 6/20 0.41
CA9 Q16790 4/20 0.41
CA12 O43570 2/20 0.41
HSD17B1 P14061 1/20 0.41
HSD17B2 P37059 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CA4 P22748 2/20 0.40
NPY5R Q15761 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
HIF1A Q16665 1/20 0.40
KIT P10721 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6345855 0.90 PTGS2 (0.44) ALDH1A1PTGS2CA1CA2CA9
SCHEMBL6352174 0.90 HSD17B2 (0.43) PTGS2CA1CA2CA9CA12
SCHEMBL6354591 0.87 CA2 (0.47) PTGS2CA2HSD17B2HDAC1HDAC8
SCHEMBL6352252 0.86 PTGS2 (0.43) ALDH1A1MAPTPTGS2CA1CA2
SCHEMBL6343217 0.85 PTGS2 (0.47) ALDH1A1HPGDPTGS2CA1CA2
SCHEMBL6345751 0.85 CA1 (0.44) PTGS2CA1CA2CA9CA12
SCHEMBL6355132 0.82 CA2 (0.42) MAPTPTGS2CA1CA2CA9
SCHEMBL6344422 0.82 PTGS2 (0.42) PTGS2CA1CA2CA9CA12
SCHEMBL6341929 0.81 PTGS2 (0.43) PTGS2CA1CA2CA9CA12
SCHEMBL6342102 0.81 CA2 (0.48) ALDH1A1MAPTPTGS2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1438293-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2004-07-21 EP claimed
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-07-03 US claimed
WO-2003027075-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-04-03 WO claimed
US-6849653-B2 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis PHARMACIA CORPORATION (US) 2005-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation IRAK4, NLRP3, CXCL8 MAPK1 650/4885ALDH1A1 1056/4885MAPT 3251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.